Thomson Reuters

DSM Announces Receipt of Final Competition Clearance for Acquisition of Martek


Source: Thomson Reuters

Royal DSM N.V. (NYSE Euronext: DSM KON), the global Life Sciences and Materials Sciences company headquartered in the Netherlands, announces today that it has received the unconditional clearance of the Counsel of the National Competition Commission in Spain for its previously announced tender offer for all outstanding shares of common stock of Martek Biosciences Corporation (NASDAQ: MATK) at a price of $31.50 per share (the 'Offer'). This was the final clearance needed under applicable antitrust and competition laws and this condition of the Offer is thus completely satisfied.


The Offer remains subject to the satisfaction of certain other conditions. The Offer is scheduled to expire at 5:00 p.m. (New York City time) on Friday, 18 February 2011, unless the Offer is extended.  



Martek is a leader in the innovation, development, production and sale of high-value products from microbial sources that promote health and wellness through nutrition. Martek's technology platform consists of its core expertise, broad experience and proprietary technology in areas such as microbial biology, algal genomics, fermentation and downstream processing. This technology platform has resulted in Martek's development of a number of products, including the company's flagship product, life'sDHA(TM), a sustainable and vegetarian source of algal DHA (docosahexaenoic acid) important for brain, heart and eye health throughout life for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements and animal feeds.  Martek also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula and follow-on formulas. Martek's subsidiary, Amerifit Brands, develops, markets and distributes branded consumer health and wellness products and holds leading brand positions in all of its key product categories. Amerifit products are sold in most major mass, club, drug, grocery and specialty stores and include: Culturelle®, a leading probiotic supplement; AZO, the leading OTC brand addressing symptom relief and detection of urinary tract infections; and Estroven®, the leading all-natural nutritional supplement brand addressing the symptoms of menopause.


For more information on Martek Biosciences, visit For a complete list of life'sDHA(TM) and life'sARA(TM) products, visit For more information about Amerifit Brands, visit


DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about €8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information:


For more information:

DSM Corporate Communications

Herman Betten

tel. +31 (0) 45 5782017                    

fax +31 (0) 45 5740680                    



DSM Investor Relations

Hans Vossen

tel. +31 (0) 45 5782864

fax +31 (0) 45 5782595

Brunswick Group

Jennifer Lowney/Justin Dini

Tel +1 212 333 3810




Brunswick Group

Kate Miller/Jonathan Glass

Tel +44 20 7396 3544



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: DSM N.V. via Thomson Reuters ONE


Customer comments

No comments were found for DSM Announces Receipt of Final Competition Clearance for Acquisition of Martek. Be the first to comment!